# Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects

> **NCT07058779** · PHASE1 · RECRUITING · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 26 (estimated)

## Conditions studied

- Safety Issues

## Interventions

- **DRUG:** SSS55

## Key facts

- **NCT ID:** NCT07058779
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-04
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07058779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07058779, "Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07058779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*